<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642027</url>
  </required_header>
  <id_info>
    <org_study_id>RT2020-01</org_study_id>
    <nct_id>NCT04642027</nct_id>
  </id_info>
  <brief_title>PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy</brief_title>
  <acronym>PERYTON</acronym>
  <official_title>PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy of Biochemical Failure After Radical Prostatectomy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR)&#xD;
      within 5 years.&#xD;
&#xD;
      The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy&#xD;
      (sEBRT). sEBRT can provide long-term disease control; with 5 year biochemical&#xD;
      progression-free survival (bPFS) up to 60% and with most treatment failures in the first 2&#xD;
      years after sEBRT.&#xD;
&#xD;
      The main goal of this project is to investigate whether the oncologic outcome in patients&#xD;
      with post-prostatectomy recurrent PCa can be improved, by increasing the biological effective&#xD;
      radiation dose using a hypofractionated schedule of 20 x 3 = 60 Gy.&#xD;
&#xD;
      The study is designed as a prospective open phase III randomized multicenter trial. All&#xD;
      patients with biochemical recurrence with a PSA &lt; 1.0 ng/ml after radical prostatectomy for&#xD;
      prostate cancer without evidence of lymph nodes or distance metastases will be included. PSA&#xD;
      progression after prostatectomy defined as two consecutive rises with the final PSA &gt; 0.1&#xD;
      ng/mL or three consecutive rises will be included.&#xD;
&#xD;
      All eligible patients will be randomized to one of the following two treatment arms:&#xD;
&#xD;
      Arm 1 = Conventional sEBRT to apply a total dose of 70 Gy in 35 daily fractions of 2 Gy&#xD;
      during 7 weeks.&#xD;
&#xD;
      Arm 2 = Hypofractionated sEBRT to apply a total dose of 60 Gy in 20 fractions of 3 Gy during&#xD;
      4 weeks.&#xD;
&#xD;
      The primary endpoint will be the 5-year progression-free survival (PFS) after treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 randomised arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>5-year progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as biochemical progression, clinical progression, loco-regional or distant progression or start with hormonal therapy, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute grade ≥ 2 gastrointestinal toxicity</measure>
    <time_frame>Up to 3 months after completion of the RT</time_frame>
    <description>As assessed using physician-reported score: Common Terminology Criteria for adverse events version 5.0 (CTCAE-5) toxicity score with a scale of 1 - 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute grade ≥ 2 genitourinary toxicities</measure>
    <time_frame>Up to 3 months after completion of the RT</time_frame>
    <description>As assessed using physician-reported score using questionnaires (CTCAE 5.0 toxicity score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late grade ≥ 2 gastrointestinal toxicity</measure>
    <time_frame>Up to 5 years after completion of the RT</time_frame>
    <description>As assessed using physician-reported score (CTCAE 5.0 toxicity score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late grade ≥ 2 genitourinary toxicity</measure>
    <time_frame>Up to 5 years after completion of the RT</time_frame>
    <description>Using physician-reported score (CTCAE 5.0 toxicity score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after radiation</measure>
    <time_frame>Up to 5 years after completion of the RT</time_frame>
    <description>As assessed using patient-reported questionnaires: measurend with European platform of cancer research-QLQ C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from randomisation to the date of metastases reported by CT scan, MRI scan or PSMA-PET/CT during the follow up (date scan).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Prostate cancer-specific mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute grade ≥ 2 gastrointestinal toxicity</measure>
    <time_frame>Up to 3 months after completion of the RT</time_frame>
    <description>Using patient-reported questionnaires (Radiation Therapy Oncology Group (RTOG) / European platform of cancer research (EORTC) toxicity questionnaires with grade 1 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute grade ≥ 2 genitourinary toxicities</measure>
    <time_frame>Up to 3 months after completion of the RT</time_frame>
    <description>Using patient-reported questionnaires (Radiation Therapy Oncology Group (RTOG) / European platform of cancer research (EORTC) toxicity questionnaires with grade 1 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late grade ≥ 2 genitourinary toxicity</measure>
    <time_frame>Up to 5 years after completion of the RT</time_frame>
    <description>Using patient-reported questionnaires (Radiation Therapy Oncology Group (RTOG) / European platform of cancer research (EORTC) toxicity questionnaires with grade 1 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life after radiation</measure>
    <time_frame>Up to 5 years after completion of the RT</time_frame>
    <description>As assessed using patient reported quatinnaires: European platform of cancer research-Quality of Life Questionnaire - Prostate Cancer Module (PR 25).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Cancer Recurrence</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional sEBRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated sEBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional sEBRT</intervention_name>
    <description>A total dose of70 Gy in 35 daily fractions of 2 Gy during 7 weeks</description>
    <arm_group_label>Conventional</arm_group_label>
    <other_name>Conventional salvage external beam radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated sEBRT</intervention_name>
    <description>A total dose of 60 Gy in 20 daily fractions of 3 Gy during 4 weeks</description>
    <arm_group_label>Hypofractionation</arm_group_label>
    <other_name>Hypofractionated salvage external beam radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with prostate adenocarcinoma treated with radical prostatectomy;&#xD;
&#xD;
          -  Tumour stage pT2-4, R0-1, pN0, or cN0, cNx according to the UICC TNM 2009, only with&#xD;
             Gleason score available;&#xD;
&#xD;
          -  No lymph node or distant metastases. A recent PSMA-PET scan (&lt; 60 days) without&#xD;
             evidence of lymph node or distant metastases;&#xD;
&#xD;
          -  PSA progression after prostatectomy defined as two consecutive rises with the final&#xD;
             PSA &gt; 0.1 ng/mL or 3 consecutive rises. The first value must be measured at least 6&#xD;
             weeks after radical prostatectomy;&#xD;
&#xD;
          -  PSA at inclusion &lt; 1.0 ng/mL;&#xD;
&#xD;
          -  WHO performance status 0-2 at inclusion;&#xD;
&#xD;
          -  Age at inclusion between 18 and 80 years;&#xD;
&#xD;
          -  Written (signed and dated) informed consent prior to registration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior pelvic irradiation, (chemo)hormonal therapy or orchiectomy;&#xD;
&#xD;
          -  Previous or concurrent active invasive cancers other than superficial non-melanoma&#xD;
             skin cancers;&#xD;
&#xD;
          -  Patients with positive nodes or with distant metastases based on the surgical specimen&#xD;
             of lymphadenectomy or the following minimum diagnostic workup: PSMA-PET/CT scan, 60&#xD;
             days prior to registration;&#xD;
&#xD;
          -  Double-sided metallic hip prosthesis;&#xD;
&#xD;
          -  Inability or unwillingness to understand the information on trial-related topics, to&#xD;
             give informed consent or to fill out QoL questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Aluwini, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Staal, MD</last_name>
    <phone>0031655257985</phone>
    <email>f.h.e.staal@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>P. Veldhuijzen van Zanten</last_name>
    <phone>0031503614659</phone>
    <email>peryton@rt.umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radiotherapy Institute Friesland</name>
      <address>
        <city>Leeuwarden</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. De Jong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D. Haverkort, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R.J. Smeenk, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B. Vanneste, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina-Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>T.C.G. Budiharto, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verbeeten Institute</name>
      <address>
        <city>Tilburg</city>
        <state>Noord-Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M.A.E. van de Sande, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC (Location VUmc)</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J. van Moorselaar, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep</name>
      <address>
        <city>Deventer</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>D. Haverkort, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B. Hollman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S. Rademakers, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L. Incocci, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F.H.E. Staal, MD.</last_name>
      <email>PERYTON@rt.umcg.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Shafak Al-Uwini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PSMA-PET/CT</keyword>
  <keyword>Salvage</keyword>
  <keyword>Hypofractionation</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

